RenovoRx RNXT
NASDAQ RNXT
$1.22 +0.04 (+3.39%)
At close: Nov 11, 2026 · 4:00 PM EST

RenovoRx (RNXT) EBITDA Margin (2025 - 2026)

Updated

RenovoRx's EBITDA Margin came in at -367.88% for Q2 2026, up 29.75 percentage points from -397.63% a year earlier and up 248.11 percentage points from the prior quarter.

Analysis

RenovoRx (RNXT) EBITDA Margin (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, RenovoRx reported EBITDA Margin of -634.31%; for FY2025, it was -935.89%, up 24575.74 percentage points from FY2024.

  • Going back by year, EBITDA Margin was -25511.63% in FY2024.
  • Business Quant data shows RNXT's EBITDA Margin at -615.99% (Q1 2026), -1479.83% (Q4 2025) and -827.07% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Thermo Fisher Scientific 266.22 Bn 242.86 Bn 5.13 Bn 25.44%
2 Abbott Laboratories 191.31 Bn 165.77 Bn 7.39 Bn 20.09%
3 Danaher 166.16 Bn 145.82 Bn 3.84 Bn 30.00%
4 Intuitive Surgical 155.98 Bn 136.40 Bn 2.08 Bn 25.90%
5 Medtronic 130.05 Bn 96.18 Bn 6.34 Bn 25.55%
6 Stryker 123.40 Bn 109.59 Bn 4.25 Bn -
7 Boston Scientific 64.81 Bn 60.48 Bn 3.43 Bn 23.14%
8 Edwards Lifesciences 59.87 Bn 43.18 Bn 1.35 Bn 20.05%
9 Medline 53.84 Bn 50.96 Bn 1.93 Bn 9.79%
10 RenovoRx 56.86 Mn 17.54 Mn 878,000.00 -303.10%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -303.10%
Jun 30, 2026 -367.88%
Mar 31, 2026 -615.99%
Dec 31, 2025 -1,479.83%
Sep 30, 2025 -827.07%
Jun 30, 2025 -397.63%
Mar 31, 2025 -1,578.17%
API Access

RenovoRx EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RNXT&period=max&api_key=YOUR_API_KEY